Skip to main content
. Author manuscript; available in PMC: 2022 Jan 1.
Published in final edited form as: Breast Cancer Res Treat. 2020 Sep 17;185(1):73–84. doi: 10.1007/s10549-020-05927-5

Fig. 4. Combined treatment with metformin and BMS-754807 synergistically enhances p27 and p-p27(T187) but reduces Skp2.

Fig. 4

Immunoblots (a) and quantification (b-d) of the indicated proteins in the HCC1806 cell line. Cells were treated for 48 hours with metformin (5mM), BMS-754807 (15μM), or the drug combination.